BioSpace News Archive

Frontage Laboratories, Inc. today announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera).

Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic diseases, today announced positive topline results from a Phase 3 clinical trial of ecnoglutide (XW003) in Chinese adults with type 2 diabetes mellitus (T2DM).

European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1 -Positive Non-Small Cell Lung Cancer and NTRK -Positive Solid Tumors.

Scribe Therapeutics Inc. today announced that Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT in San Francisco, CA.

Apogee Therapeutics, Inc. today announced that Michael Henderson, M.D., Chief Executive Officer of Apogee, will present at the 42nd Annual J.P. Morgan Conference on Tuesday, January 9, 2024 at 7:30 a.m. P.T. / 10:30 a.m. E.T.

Pulnovo Medical Limited recently announced that it has successfully obtained Humanitarian Use Device (HUD) designation from the US FDA and approval from China’s National Drug Administration (NMPA) for the PADN Catheter and Generator.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 8:15 a.m. PT in San Francisco, CA.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, dosed the first patient in the Phase I/II trial in men with metastatic castration-resistant prostate cancer (mCRPC) on December 27, 2023.

Akari Therapeutics, Plc announced that it closed a private placement financing with existing investors, Akari Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., on December 29, 2023, resulting in gross proceeds of approximately $2 million.

Kindbody announced today that Founder and Executive Chairman, Gina Bartasi, is scheduled to present and provide a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 8:00 a.m. PT (11:00 a.m. ET) in San Francisco, CA.